Makers of generics should develop abuse-resistant oxycodone

04/22/2013 | New York Times (tiered subscription model), The

Makers of generic drugs should market their own abuse-resistant formulations of the painkiller OxyContin, or oxycodone, following an FDA ruling that will block the entry of generic versions of the original formulation from the market, according to this editorial.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA